-2.95 (-0.20%) Cipla’s consumer healthcare arm - Cipla Health has reportedly plans to revitalize its over-the-counter (OTC) consumer business through more in-house launches and brand acquisitions in the coming quarters.
The company is looking at new product launches in segments such as gastrointestinal, pain and analgesic, cough and cold and nutritional supplements. It is also actively looking at any kind of inorganic growth through mergers and acquisitions.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.